A study on comparative efficacy of anti tubercular chemoprophylaxis with 2 different regimens: 2 months of rifampicin and pyrazinamide and 6 months of daily isoniazid and rifampicin in HIV infected tuberculin reactors
Human immune-virus (HIV) infection is the most significant risk factor for progression of latent mycobacterium tuberculosis (MTB) infection to active tuberculosis. Tuberculosis reactivation among human immunodeficiency virus (HIV) infected cases can be prevented by anti tubercular chemoprophylaxis....
Main Author: | Prasad BNBM |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2006-01-01
|
Series: | Lung India |
Subjects: | |
Online Access: | http://www.lungindia.com/article.asp?issn=0970-2113;year=2006;volume=23;issue=2;spage=64;epage=69;aulast=Prasad |
Similar Items
-
Chemoprophylaxis of leprosy with rifampicin in contacts of multibacillary patients: study protocol for a randomized controlled trial
by: Daiane Santos dos Santos, et al.
Published: (2018-04-01) -
Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study
by: Geetha Ramachandran, et al.
Published: (2023-01-01) -
An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++
by: Liesbeth F Mieras, et al.
Published: (2018-10-01) -
Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro
by: Claudia Teresa Vieira de Souza, et al.
Published: (2009-05-01) -
Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.
by: Thomas Pouplin, et al.
Published: (2014-01-01)